A method for detecting MERS-CoV at high sensitivity and specificity using IgY antibodies that bind to MERS-CoV N protein, its fragments and domains. Isolated or purified IgY monospecific antibodies to MERS-CoV N protein.

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

The application describes methods for detecting site specific proteases indicative of infection by a protease-generating pathogen. The application also describes fusion proteins for use in the methods, DNAs encoding the proteins and cells that express them. Particular applications are described including fusion proteins and methods for detecting corona viruses,.

such as SARS CoV2. Method for protease and pathogen detection described in the application include protease amplification methods and methods using inhibitors to increase sensitivity and specificity.

In one aspect, a sensor for detecting SARS-CoV-2 virus in a sample, e.g., a blood sample, is disclosed, which includes a graphene layer, a plurality of binding agents coupled to said graphene layer to generate a functionalized graphene layer, where the binding agents exhibit specific binding to at least one epitope of SARS-CoV-2 virus, and a plurality of electrical conductors electrically coupled to said functionalized graphene layer for measuring an electrical property (e.g., DC electrical resistance) of the functionalized graphene layer. While in some embodiments such binding agents are monoclonal antibodies, in other embodiments they can be polyclonal antibodies.

Methods, systems, and kits for detection, diagnosis, monitoring, and/or treatment of viral infections such as represented by the COVID-19 disease are described. The methods, systems, and kits are capable of detection of salivary biomarkers which correlate with, and are indicative of, COVID-19 in a subject. Detection of the biomarkers in a saliva sample provides opportunities for a COVID-19 or other viral detection assay which is non-invasive, produces rapid results, and can be implemented in the field on a wide geographic basis for individualized screening or mass screenings for COVID-19 or other viral infections.

Described herein in one embodiment is software, which may be downloaded to a device, to guide a user through administration of a test. Test results may be uploaded, manually or automatically, to a device or communicated remotely through a network. In an embodiment, the test is a rapid test. In an embodiment, the rapid test detects presence of COVID-19. In an embodiment, the rapid test detects COVID-19 or influenza. In an embodiment, the rapid test detects influenza A or influenza B. In an embodiment, the rapid test detects a target nucleic acid. In an embodiment, the target nucleic acid represents one of a viral, bacterial, fungal, parasitic or protozoan pathogen. Each of the rapid tests may be self administrable.

Described herein in one embodiment is a computer-implemented method comprising accessing information representing a detection component of a diagnostic test and determining, based at least in part on the information representing the detection component of the diagnostic test, results of the diagnostic test. Described herein in one embodiment is a method of performing a diagnostic test on a subject. In one embodiment, the method comprises obtaining a sample from the subject, processing the sample, analyzing the sample with a detection component of the diagnostic test, and performing a computer-implemented method comprising accessing information representing the detection component of a diagnostic test, and determining, based at least in part on the information representing the detection component of the diagnostic test, results of the diagnostic test.

Described herein in one embodiment is software, which may be downloaded to a device, to guide a user through administration of a test. Test results may be uploaded, manually or automatically, to a device or communicated remotely through a network. In an embodiment, the test is a rapid test. In an embodiment, the rapid test detects presence of COVID-19. In an embodiment, the rapid test detects COVID-19 or influenza. In an embodiment, the rapid test detects influenza A or influenza B. In an embodiment, the rapid test detects a target nucleic acid. In an embodiment, the target nucleic acid represents one of a viral, bacterial, fungal, parasitic or protozoan pathogen. Each of the rapid tests may be self administrable.

Disclosed is a method for detecting and monitoring the presence, development and propagation of at least one infectious agent such as a bacterium or a virus, which is remarkable in that it includes the following steps: Subdivide the considered geographic area into area cells; Determine and identify in each area cell the points of presence, passing through or frequentation by human and/or animal beings likely to be infected by the infectious agent or by human and/or animal beings likely to be hosts to the infectious agent; and Install at each identified point in each area cell an autonomous device for detection of the infectious agent present in the environment surrounding the device by analysis and identification. Also disclosed is a device for executing the process.

The invention is an analytical toilet and a method. The toilet, includes a bowl adapted to receive urine. A passage is provided for transferring a sample of the urine to a detection system. The detection system is configured to receive the sample and detect a virus. When the sample is brought into contact with the detection system, the detection system indicates the presence of a virus by generating a distinct signal. Preferably, the detection system makes use of a nucleic acid amplification test (NAAT), such as a quantitative PCR instrument. The method makes use of the analytical toilet and is designed to detect the presence or absence of targeted genetic material, preferably genetic material from a virus, such as SARS-CoV-2.